Leukemia Research
Volume 34, Issue 4 , Pages 409-410 , April 2010

Right and left shifts for age in MDS

  • Semra Paydas

      Affiliations

    • Corresponding Author InformationTel.: +90 322 3386060; fax: +90 322 3386153.

Received 30 August 2009

References 

  1. Giagounidis AAN. Myelodysplasia or myelodysplastic syndrome. Leuk Res. 2009;1019
  2. Anargyrou K, Vassilakopoulos TP, Angelopoulou MK, Terpos E. Incorporating novel agents in the treatment of myelodysplastic syndromes. Leuk Res. 2009;[Epub ahead of print, August 3]
  3. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton HR, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  4. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–736
  5. Valent P, Wieser R. Update on genetic and molecular markers associated with myelodysplastic syndromes. Leuk Lymphoma. 2009;50:341–348
  6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  7. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. Washington, DC: IARC Press; 2001;
  8. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510
  9. Golagan R, Georgescu D, Tatic A, Radulescu I, Vasilache D. Epidemiologic data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania. Leuk Res. 2009;33(11):1556–1561
  10. Cazzola M, Malcovati L. Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536–558
  11. Germing U, Strupp C, Küngden A, Bowen D, Aul C, Haas C, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89:905–910
  12. Gattermann N, Hofmann WK, MeeBen A, Shmitz S, Tsamaloukas A, Vollmer T, et al. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. Onkologie. 2008;31:477–484
  13. Paydas S, Kocak R. Younger age observation in myelodysplastic syndromes. Leuk Res. 1996;30:367
  14. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005;19:767–775
  15. Paydas S. Young age MDS: differences between Western and Eastern countries. Leuk Res. 2006;362–364
  16. Breccia M, Mengarelli A, Mancini M, Biondo F, Gentilini F, Latagliata R, et al. Myelodysplastic syndromes in patients under 50 years old: a single institution experience. Leuk Res. 2005;29:749–754
  17. Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic Syndrome: a co-operative study based on 838 cases. Anemia study group of the ministry of health and welfare. Leuk Res. 1995;19:219–225
  18. Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17:305–313
  19. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, Suwanwela N, Chaimongkol B, Jootar S, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res. 1998;22:453–460
  20. Chatterjee T, Dixit A, Mohapatra M, Tyagi S, Gupta PK, Mishra P, et al. Clinical, hematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in young age. Eur J Haematol. 2004;73:93–97
  21. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083–1091
  22. Picozzi VJ, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol. 1986;4:589–595
  23. Ballen KK, Antin JH. Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am. 1993;7:477–493
  24. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7:81–107

PII: S0145-2126(09)00471-8

doi: 10.1016/j.leukres.2009.09.011

Leukemia Research
Volume 34, Issue 4 , Pages 409-410 , April 2010

Article Tools